spacer
home > pmps > autumn 2017 > handling hazards
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Handling Hazards

The pharmaceutical industry’s ongoing search for new medicines capable of achieving greater therapeutic activity while also reducing dosage amounts and minimising undesirable side effects has led to an intense research focus on more potent drug molecules. As a result, the number of highly potent active pharmaceutical ingredients (HPAPIs) under development over the past few years has been steadily increasing, with HPAPIs present in around a quarter of medicines in the pharma pipeline (1).

The increasing demand from the oncology sector has been driving this growth, with around 60% of HPAPIs being developed as anticancer agents (1). With HPAPIs increasingly being used to treat chronic diseases such as diabetes and heart disease, this global market is expected to be worth an estimated $34.8 billion by 2025, up from $14.4 billion in 2016, according to figures from Grand View Research (2).

Highly Potent and Challenging

As HPAPIs are able to produce greater pharmacological effects at lower concentrations, smaller amounts of the drug can be administered to patients, potentially leading to fewer side effects as well as causing less damage to healthy tissue surrounding the diseased area. Furthermore, as lower administration frequencies can be used, patient adherence to medication schemes can potentially be improved. However, the greater potency of HPAPIs also presents several additional challenges to developers and manufacturers in terms of their safe handling.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
As a qualified individual for investigational medicinal products and APIs with over 25 years’ experience within the sector, Carla Brandolini is a Senior GMP QA Specialist at Aptuit, responsible for ensuring and overseeing GMP compliance and batch release. She is also an expert in dealing with regulatory authority audits and follow-ups, as well as the management of controlled substances used for clinical and toxicological studies.

With over 20 years’ experience in the pharma industry, Jean-Francois Carniaux is a highly skilled PhD-trained scientist, whose expertise focuses on API analytical and chemistry development programmes, from early development to late clinical phase and commercial manufacture. As Director of API Development and Manufacturing for the Aptuit site in Verona, Italy, he combines technical expertise in chemical development, including solid-state chemistry and scale-up troubleshooting, with a breath of experience in project leadership and management.

As Vice President, Global Head of CMC for Aptuit, Mario Maio blends scientific knowledge with business acumen, leading his team to provide development expertise for all CMC disciplines and cGMP manufacturing. During his 25-year career, he has developed and monitored early- and late-stage formulation projects and provided strategic direction for the implementation of drug delivery systems, translating innovative ideas into products.

Starting his career in 1996 as a quality co-ordinator, Iain Rusling has gathered a wealth of skills and experience working with some of the biggest companies in the industry, leading him to become Vice President of Global Quality Management and EHS at Aptuit. Iain is an expert in quality management processes thanks to his long-standing experience in different cGMP environments, allowing him to drive initiatives, foster continuous improvement and maintain high levels of accountability throughout the entire area of responsibility.
spacer
Carla Brandolini, Jean-Francois Carniaux, Mario Maio and Iain Rusling
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Acquires KWS BioTest

WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 11, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. The addition of KWS enhances Charles River’s discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th – 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement